JP2013507361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507361A5 JP2013507361A5 JP2012533139A JP2012533139A JP2013507361A5 JP 2013507361 A5 JP2013507361 A5 JP 2013507361A5 JP 2012533139 A JP2012533139 A JP 2012533139A JP 2012533139 A JP2012533139 A JP 2012533139A JP 2013507361 A5 JP2013507361 A5 JP 2013507361A5
- Authority
- JP
- Japan
- Prior art keywords
- isoflavone
- animal
- administered
- amount
- package
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims 20
- 235000008696 isoflavones Nutrition 0.000 claims 20
- 238000000034 method Methods 0.000 claims 19
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims 17
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims 6
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 claims 4
- 229930182478 glucoside Natural products 0.000 claims 4
- OZBAVEKZGSOMOJ-MIUGBVLSSA-N glycitin Chemical compound COC1=CC(C(C(C=2C=CC(O)=CC=2)=CO2)=O)=C2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZBAVEKZGSOMOJ-MIUGBVLSSA-N 0.000 claims 4
- 150000002515 isoflavone derivatives Chemical class 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 208000001076 sarcopenia Diseases 0.000 claims 3
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 claims 2
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 claims 2
- XJTZHGNBKZYODI-UHFFFAOYSA-N Glycitin Natural products OCC1OC(Oc2ccc3OC=C(C(=O)c3c2CO)c4ccc(O)cc4)C(O)C(O)C1O XJTZHGNBKZYODI-UHFFFAOYSA-N 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 235000007240 daidzein Nutrition 0.000 claims 2
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- 235000019126 equol Nutrition 0.000 claims 2
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 claims 2
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 claims 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims 2
- 235000006539 genistein Nutrition 0.000 claims 2
- 229940045109 genistein Drugs 0.000 claims 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims 2
- 150000008131 glucosides Chemical class 0.000 claims 2
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 claims 2
- 235000008466 glycitein Nutrition 0.000 claims 2
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 claims 2
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 claims 2
- -1 malonyl glucosides Chemical class 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 230000037208 balanced nutrition Effects 0.000 claims 1
- 235000019046 balanced nutrition Nutrition 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27863309P | 2009-10-09 | 2009-10-09 | |
| US61/278,633 | 2009-10-09 | ||
| PCT/US2010/002722 WO2011043827A1 (en) | 2009-10-09 | 2010-10-08 | Methods for preventing or treating sarcopenia and muscle atrophy in animals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013507361A JP2013507361A (ja) | 2013-03-04 |
| JP2013507361A5 true JP2013507361A5 (https=) | 2013-11-21 |
| JP6122638B2 JP6122638B2 (ja) | 2017-04-26 |
Family
ID=43857050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012533139A Active JP6122638B2 (ja) | 2009-10-09 | 2010-10-08 | 動物のサルコペニア及び筋萎縮症を予防又は治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9301941B2 (https=) |
| EP (1) | EP2485740B1 (https=) |
| JP (1) | JP6122638B2 (https=) |
| CN (1) | CN102573857A (https=) |
| AU (1) | AU2010303872B2 (https=) |
| BR (1) | BR112012008238A2 (https=) |
| CA (1) | CA2776950C (https=) |
| ES (1) | ES2688447T3 (https=) |
| IN (1) | IN2012DN02624A (https=) |
| MX (1) | MX2012004118A (https=) |
| RU (1) | RU2558534C2 (https=) |
| WO (1) | WO2011043827A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11090313B2 (en) | 2010-05-20 | 2021-08-17 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
| AU2012268036B2 (en) * | 2011-06-06 | 2017-04-06 | THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF STATE OF THE DEPARTMENT OF VETERANS AFFAIRS | Methods of inhibiting muscle atrophy |
| US9913823B2 (en) * | 2011-10-18 | 2018-03-13 | Amorepacific Corporation | SIRT 1 activator including syringaresinol |
| WO2015166887A1 (ja) * | 2014-04-28 | 2015-11-05 | サントリーホールディングス株式会社 | ケルセチン配糖体を含有する筋萎縮抑制剤 |
| EP3256004A1 (en) | 2015-02-13 | 2017-12-20 | Mars, Incorporated | Pet food feeding system |
| KR20170002846A (ko) | 2015-06-30 | 2017-01-09 | (주)아모레퍼시픽 | 콩잎 추출물을 유효성분으로 함유하는 근질환 억제 및 예방용 조성물 |
| GB201522304D0 (en) | 2015-12-17 | 2016-02-03 | Mars Inc | Food product for reducing muscle breakdown |
| GB201721627D0 (en) | 2017-12-21 | 2018-02-07 | Mars Inc | Pet food product |
| CN108635571B (zh) * | 2018-07-19 | 2021-10-22 | 西安交通大学医学院第一附属医院 | 鸢尾素(irisin)在制备预防及治疗重症急性胰腺炎药物中的应用 |
| CA3156846A1 (en) * | 2019-10-04 | 2021-04-08 | Suntory Holdings Limited | Composition for suppression of decrease in muscle mass, prevention of decrease therein, maintenance thereof, recovery thereof or increase therein |
| KR102623198B1 (ko) * | 2020-02-26 | 2024-01-10 | 한국 한의학 연구원 | 돌콩 추출물을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소의 예방, 개선 또는 치료용 조성물 |
| RU2756154C1 (ru) * | 2020-11-13 | 2021-09-28 | Митхат Зульфугар-Оглы Гасанов | Способ диагностики саркопении у пациентов с хронической болезнью почек 5д стадии, получающих лечение программным гемодиализом |
| KR102803173B1 (ko) * | 2021-02-22 | 2025-05-07 | 한국 한의학 연구원 | 황기 추출물로부터 분리한 화합물을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생, 근감소 또는 근피로의 예방, 개선 또는 치료용 조성물 |
| WO2023140407A1 (ko) * | 2022-01-21 | 2023-07-27 | 경상국립대학교병원 | 쿠메스트롤을 포함하는 근감소증 예방 또는 치료용 약학 조성물 |
| KR102803976B1 (ko) * | 2022-04-06 | 2025-05-07 | 국립강릉원주대학교산학협력단 | 때죽나무 잎 추출물을 포함하는 근력강화용 조성물 |
| WO2025121473A1 (ko) * | 2023-12-06 | 2025-06-12 | 경상국립대학교병원 | 아세틸제니스틴을 포함하는 근감소증의 예방 또는 개선용 약학 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU166380B (https=) | 1973-07-09 | 1975-03-28 | ||
| US6887499B2 (en) * | 2000-05-22 | 2005-05-03 | Enitan A. Bababunmi | Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease |
| IL145540A0 (en) * | 2000-09-28 | 2002-06-30 | Pfizer Prod Inc | Use of growth hormone secretagogues in conjunction with physical exercise |
| AUPR846401A0 (en) * | 2001-10-25 | 2001-11-15 | Novogen Research Pty Ltd | 6-Hydroxy isoflavones, derivatives and medicaments involving same |
| JP5384777B2 (ja) * | 2001-12-18 | 2014-01-08 | 有限会社大長企画 | 強筋肉剤、抗炎症剤 |
| WO2005007676A2 (en) * | 2003-07-10 | 2005-01-27 | Rajadhyaksha V J | Glycopeptides for the treatment of als and other metabolic and autoimmune disorders |
| AU2005208934A1 (en) * | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc | Treating a viral disorder |
| ES2559777T3 (es) * | 2004-03-17 | 2016-02-15 | Nestec S.A. | Composiciones y métodos para reducir o prevenir la obesidad |
| WO2007134867A2 (en) * | 2006-05-24 | 2007-11-29 | Dsm Ip Assets B.V. | Treating muscular disorders and improving muscular function |
| CN101528214B (zh) * | 2006-08-24 | 2013-06-05 | 田纳西大学研究基金会 | 取代的n-酰基苯胺及其使用方法 |
-
2010
- 2010-10-08 WO PCT/US2010/002722 patent/WO2011043827A1/en not_active Ceased
- 2010-10-08 CN CN2010800446421A patent/CN102573857A/zh active Pending
- 2010-10-08 CA CA2776950A patent/CA2776950C/en active Active
- 2010-10-08 IN IN2624DEN2012 patent/IN2012DN02624A/en unknown
- 2010-10-08 RU RU2012118686/13A patent/RU2558534C2/ru not_active IP Right Cessation
- 2010-10-08 BR BR112012008238A patent/BR112012008238A2/pt not_active Application Discontinuation
- 2010-10-08 EP EP10822363.7A patent/EP2485740B1/en active Active
- 2010-10-08 JP JP2012533139A patent/JP6122638B2/ja active Active
- 2010-10-08 US US13/499,118 patent/US9301941B2/en active Active
- 2010-10-08 MX MX2012004118A patent/MX2012004118A/es active IP Right Grant
- 2010-10-08 ES ES10822363.7T patent/ES2688447T3/es active Active
- 2010-10-08 AU AU2010303872A patent/AU2010303872B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507361A5 (https=) | ||
| RU2012118686A (ru) | Способы предупреждения или лечения саркопении мышечной атрофии у животных | |
| RU2013150828A (ru) | Способы регулирования экспрессии генов сиртуинов | |
| Brodowska | Natural flavonoids: classification, potential role, and application of flavonoid analogues. | |
| Brouns | Soya isoflavones: a new and promising ingredient for the health foods sector | |
| JP2024160348A (ja) | ＰＧＣ－１α活性化用組成物 | |
| JP2012522030A5 (https=) | ||
| NZ741022A (en) | Flavonoid compositions and methods of use | |
| JP2012522030A (ja) | ヘスペレチンの生体利用率を増大させるためのフラボノイドの使用 | |
| GEP20146104B (en) | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | |
| GEP20146145B (en) | Pharmaceutical composition containing glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process of their preparation and usagetherefor improved glycemic control in patient | |
| Mah et al. | The effect of epigallocatechin-3-gallate (EGCG) on human alveolar bone cells both in vitro and in vivo | |
| JP2012511547A (ja) | イソフラボン組成物 | |
| Dwivedi et al. | Molecular structure, biological functions, and metabolic regulation of flavonoids | |
| Miniello et al. | Soy‐based formulas and phyto‐oestrogens: a safety profile | |
| Atınç et al. | Flavonoidler ve sağlık üzerine etkileri | |
| NO20092763L (no) | Isosorbid mononitrat derivater for behandling av tarmlidelser | |
| Nag et al. | The effect and mechanisms of flavonoids on inflammation and chronic metabolic diseases | |
| Ebrahimi et al. | Site-specific impact of polyphenols on the gastrointestinal microbiome | |
| Kumar et al. | Potential of flavonoids as anticancer drugs | |
| Ho | Metabolism of flavonoids | |
| He et al. | Phytoestrogens: pharmacological potential and therapeutic insights for urinary tract infections | |
| RU2013151423A (ru) | Способы и композиции, пригодные для предотвращения и лечения гиперлептинемии | |
| EA201491050A1 (ru) | Питание, предназначенное для потребления человеком | |
| JP2008542297A5 (https=) |